Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML ...
Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population J Clin Oncol, 34 (24) (2016), pp. 2851-2857 View in ScopusGoogle Scholar 4 M Aricò, M Schrappe, SP Hunger, et al. Clinical outcome of children with newly diagnosed Philadelphia...
The ability for some patients to achieve deep molecular responses, to prevent transformation, to return to near-normal life expectancy, and more recently to discontinue therapy successfully are well documented. There are currently 5 TKIs approved for CML, although approval and availability vary widely...
Dex can spread to tissues efficiently [55]. Second, the shelf life of cryopreserved Dex is longer than that of DCs [56]. Moreover, the capacity of DCs to prime tumor-specific CTLs is weakened after short-term frozen storage [57]. Third...